Aprotinin decreases the incidence of cognitive deficit following CABG and cardiopulmonary bypass: a pilot randomized controlled study.
AuthorsHarmon, Dominic C
Ghori, Kamran G
Eustace, Nicholas P
O'Callaghan, Sheila J F
O'Donnell, Aonghus P
Shorten, George D
AffiliationDepartment of Anaesthesia and Intensive Care Medicine, Cork University Hospital, , Wilton Road, Cork, Ireland. email@example.com
Cardiopulmonary Bypass/*adverse effects/methods/psychology
Cognition Disorders/etiology/*prevention & control/psychology
Coronary Artery Bypass/*adverse effects/methods/psychology
Dose-Response Relationship, Drug
Neuropsychological Tests/statistics & numerical data
Postoperative Complications/etiology/prevention & control/psychology
Psychiatric Status Rating Scales/statistics & numerical data
MetadataShow full item record
CitationCan J Anaesth. 2004 Dec;51(10):1002-9.
JournalCanadian journal of anaesthesia = Journal canadien d'anesthesie
AbstractPURPOSE: Cognitive deficit after coronary artery bypass surgery (CABG) has a high prevalence and is persistent. Meta-analysis of clinical trials demonstrates a decreased incidence of stroke after CABG when aprotinin is administrated perioperatively. We hypothesized that aprotinin administration would decrease the incidence of cognitive deficit after CABG. METHODS: Thirty-six ASA III-IV patients undergoing elective CABG were included in a prospective, randomized, single-blinded pilot study. Eighteen patients received aprotinin 2 x 10(6) KIU (loading dose), 2 x 10(6) KIU (added to circuit prime) and a continuous infusion of 5 x 10(5) KIU.hr(-1). A battery of cognitive tests was administered to patients and spouses (n = 18) the day before surgery, four days and six weeks postoperatively. RESULTS: Four days postoperatively new cognitive deficit (defined by a change in one or more cognitive domains using the Reliable Change Index method) was present in ten (58%) patients in the aprotinin group compared to 17 (94%) in the placebo group [95% confidence interval (CI) 0.10-0.62, P = 0.005); (P = 0.01)]. Six weeks postoperatively, four (23%) patients in the aprotinin group had cognitive deficit compared to ten (55%) in the placebo group (95% CI 0.80-0.16, P = 0.005); (P = 0.05). CONCLUSION: In this prospective pilot study, the incidence of cognitive deficit after CABG and cardiopulmonary bypass is decreased by the administration of high-dose aprotinin.
- Postoperative delirium and short-term cognitive dysfunction occur more frequently in patients undergoing valve surgery with or without coronary artery bypass graft surgery compared with coronary artery bypass graft surgery alone: results of a pilot study.
- Authors: Hudetz JA, Iqbal Z, Gandhi SD, Patterson KM, Byrne AJ, Pagel PS
- Issue date: 2011 Oct
- Donepezil for cognitive decline following coronary artery bypass surgery: a pilot randomized controlled trial.
- Authors: Doraiswamy PM, Babyak MA, Hennig T, Trivedi R, White WD, Mathew JP, Newman MF, Blumenthal JA
- Issue date: 2007
- Tranexamic acid and aprotinin in primary cardiac operations: an analysis of 220 cardiac surgical patients treated with tranexamic acid or aprotinin.
- Authors: Dietrich W, Spannagl M, Boehm J, Hauner K, Braun S, Schuster T, Busley R
- Issue date: 2008 Nov
- Coronary artery bypass grafting with single cross-clamp results in fewer persistent neuropsychological deficits than multiple clamp or off-pump coronary artery bypass grafting.
- Authors: Hammon JW, Stump DA, Butterworth JF, Moody DM, Rorie K, Deal DD, Kincaid EH, Oaks TE, Kon ND
- Issue date: 2007 Oct
- Full-dose aprotinin use in coronary artery bypass graft surgery: an analysis of perioperative pharmacotherapy and patient outcomes.
- Authors: Royston D, Levy JH, Fitch J, Dietrich W, Body SC, Murkin JM, Spiess BD, Nadel A
- Issue date: 2006 Nov